I-Mab is a biotechnology business based in the US. I-Mab shares (IMAB) are listed on the NASDAQ and all prices are listed in US Dollars. I-Mab employs 228 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in I-Mab
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IMAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
I-Mab stock price (NASDAQ: IMAB)Use our graph to track the performance of IMAB stocks over time.
I-Mab shares at a glance
|Latest market close||$81.07|
|52-week range||$28.29 - $85.40|
|50-day moving average||$76.68|
|200-day moving average||$61.94|
|Wall St. target price||$89.73|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.06|
Buy I-Mab shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy I-Mab stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
I-Mab price performance over time
|1 week (2021-07-13)||N/A|
|1 month (2021-06-24)||-0.26%|
|3 months (2021-04-20)||N/A|
|6 months (2021-01-20)||N/A|
|1 year (2020-07-20)||N/A|
|2 years (2019-07-20)||N/A|
|3 years (2018-07-20)||N/A|
|5 years (2016-07-20)||N/A|
Is I-Mab under- or over-valued?
Valuing I-Mab stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of I-Mab's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
I-Mab's P/E ratio
I-Mab's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 73x. In other words, I-Mab shares trade at around 73x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
I-Mab's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $168.3 million.
The EBITDA is a measure of a I-Mab's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.5 billion|
|Operating margin TTM||10.08%|
|Gross profit TTM||$1.5 billion|
|Return on assets TTM||2.41%|
|Return on equity TTM||14.06%|
|Market capitalisation||$6 billion|
TTM: trailing 12 months
Shorting I-Mab shares
There are currently 2.1 million I-Mab shares held short by investors – that's known as I-Mab's "short interest". This figure is 0.7% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting I-Mab shares can be evaluated.
I-Mab's "short interest ratio" (SIR)
I-Mab's "short interest ratio" (SIR) is the quantity of I-Mab shares currently shorted divided by the average quantity of I-Mab shares traded daily (recently around 514127.57793765). I-Mab's SIR currently stands at 4.17. In other words for every 100,000 I-Mab shares traded daily on the market, roughly 4170 shares are currently held short.
However I-Mab's short interest can also be evaluated against the total number of I-Mab shares, or, against the total number of tradable I-Mab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case I-Mab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 I-Mab shares in existence, roughly 30 shares are currently held short) or 0.0704% of the tradable shares (for every 100,000 tradable I-Mab shares, roughly 70 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against I-Mab.
Find out more about how you can short I-Mab stock.
I-Mab share dividends
We're not expecting I-Mab to pay a dividend over the next 12 months.
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; and PT Kalbe Genexine Biologics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. .
I-Mab in the news
Hedge Funds Have Never Been This Bullish On I-Mab (IMAB)
I-Mab (NASDAQ:IMAB) Shareholders Have Enjoyed An Impressive 143% Share Price Gain
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
Frequently asked questionsWhat percentage of I-Mab is owned by insiders or institutions?
Currently 0.841% of I-Mab shares are held by insiders and 38.336% by institutions. How many people work for I-Mab?
Latest data suggests 228 work at I-Mab. When does the fiscal year end for I-Mab?
I-Mab's fiscal year ends in December. Where is I-Mab based?
I-Mab's address is: West Tower, OmniVision, Shanghai, China, 201210 What is I-Mab's ISIN number?
I-Mab's international securities identification number is: US44975P1030 What is I-Mab's CUSIP number?
I-Mab's Committee on Uniform Securities Identification Procedures number is: 44975P103
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert